Intervention: Pazopanib
Trial phase: Phase 2
ATC code: L01EX03 | L01XE11
SMILES: Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: Pazopanib was given at a dose of 800 mg orally once per day for 28 day cycles (+/- 3 days). Patients received treatment as long as they were receiving clinical benefit.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of small cell neuroendocrine carcinoma based on either histology or cytology with radiologically-confirmed progressive disease.
Participants should have received first-line chemotherapy and may have had up to two prior chemotherapy regimens. Radiation therapy may have been part of the permitted prior therapy.
Participants with brain metastases will be allowed if they have been treated with surgery and/or radiation therapy more than 21 days prior, are asymptomatic, and are stable for at least one week off steroids.
18 years of age or older
ECOG Performance status of 0, 1 or 2
Ability to swallow and retain oral medication
Disease must be measurable according to RECIST 1.1
Adequate organ function as defined in the protocol

Exclusion Criteria:

Prior malignancy except for participants that have been disease-free for 3 years or with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma
History or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for one week prior to first dose of study drug.
Clinically significant gastrointestinal abnormalities
Presence of uncontrolled infection
Prolongation of corrected QT interval (QTc) > 480msecs
History of any one or more of the following cardiovascular conditions within the past 6 months: cardiac angioplasty or stenting; myocardial infarction; unstable angina; symptomatic peripheral vascular disease; Class III or IV congestive heart failure
Poorly controlled hypertension
History of cerebrovascular accident including transient ischemic attack, pulmonary embolism or insufficiently treated deep venous thrombosis within the past 6 months
Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture or ulcer
Evidence of active bleeding or bleeding diathesis
Hemoptysis in excess of 2.5mL within 6 weeks of first dose of study drug
Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures
Use of any prohibited medication within the timeframes listed in the protocol
Use of an investigational agent, including an investigational anti-cancer agent, within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study drug
Prior use of an investigational or licensed drug that targets VEGF or VEGF receptors
Is now undergoing and/or has undergone in the 14 days immediately prior to first dose of study drug, any cancer therapy
Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib